Development of a scintillation proximity assay for human insulin-like growth factor-binding protein 4 compatible with inhibitor high-throughput screening

Analytical Biochemistry

Volumn 366, Issue 1, 2007, Pages 80-86

  Khawaja, X Z ^a  

^a PFIZER INC   (United States)

Author keywords

High throughput screening; IGF 1; IGFBP 4; NBI 31772; Receptor binding assay; Scintillation proximity assay; 125I IGF 1

Indexed keywords

BIOACTIVITY; CELL PROLIFERATION; CYTOLOGY; DIMETHYL SULFOXIDE; INSULIN; LIGANDS; MOLECULES; ORGANIC SOLVENTS; PROTEINS; SCINTILLATION;

HIGH THROUGHPUT SCREENING; IGF-1; IGFBP-4; NBI-31772; RECEPTOR BINDING ASSAYS; [^125I]IGF-1;

DIAGNOSIS;

DIMETHYL SULFOXIDE; POLYVINYLTOLUENE; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C; STREPTAVIDIN; TOLUENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; BIOTINYLATION; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; HIGH THROUGHPUT SCREENING; INCUBATION TIME; MOLECULAR INTERACTION; PRIORITY JOURNAL; SCINTILLATION; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO;

EID: 34248561757     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2007.03.011     Document Type: Article

References (13)

1. Baxter R.C. Changes in the IGF-IGFBP axis in critical illness [review]. Best Pract. Res. Clin. Endocrinol. Metab. 15 (2001) 421-434
2. Zumkeller W., and Westphal M. The IGF/IGFBP system in CNS malignancy [review]. Mol. Pathol. 54 (2001) 227-229
3. Durai R., Davies M., Yang W., Yang S.Y., Seifalian A., Goldspink G., and Winslet M. Biology of insulin-like growth factor binding protein-4 and its role in cancer [review]. Intl. J. Oncol. 28 (2006) 1317-1325
4. Mazerbourg S., Callebaut I., Zapf J., Mohan S., Overgaard M., and Monget P. Update on IGFBP-4: Regulation of IGFBP-4 levels and functions, in vitro and in vivo [review]. Growth Horm. IGF Res. 14 (2004) 71-84
5. Liu X.J., Xie Q., Zhu Y.F., Chen C., and Ling N. Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex. J. Biol. Chem. 276 (2001) 32419-32422
6. De Ceuninck F., Caliez A., Dassencourt L., Anract P., and Renard P. Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes. Arthritis Res. Ther. 6 (2004) R393-R403
7. Mackay K.B., Loddick S.A., Naeve G.S., Vana A.M., Verge G.M., and Foster A.C. Neuroprotective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro and in vivo. J. Cereb. Blood Flow Metab. 23 (2003) 1160-1167
8. Mohan S., and Baylink D.J. Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 levels in aging and age-associated diseases. Endocrine 7 (1997) 87-91
9. Carpenter J.W., Laethem C., Hubbard F.R., Eckols T.K., Baez M., and McClure D. Configuring radioligand receptor binding assays for HTS using scintillation proximity assay technology. Methods Mol. Biol. 190 (2002) 31-49
10. Wu S., and Liu B. Application of scintillation proximity assay in drug discovery [review]. BioDrugs 19 (2005) 383-392
11. 50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
12. Zhang J.H., Chung T.D., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
13. Chelius D., Baldwin M.A., Lu X., and Spencer E.M. Expression, purification, and characterization of the structure and disulfide linkages of insulin-like growth factor binding protein-4. J. Endocrinol. 168 (2001) 283-296